PROTEOME SCIENCES PLC

Board/Management Information • Sep 4, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0537Y

Proteome Sciences PLC

04 September 2015

Proteome Sciences plc

(the "Company")

Appointment of Nominated Adviser and Broker

The Board is pleased to announce that finnCap has been appointed as Nominated Adviser and sole Broker to the Company with immediate effect.

For further information please contact:

Proteome Sciences plc Christopher Pearce, Executive Chairman Dr. Ian Pike, Chief Operating Officer Geoff Ellis, Finance Director	Tel: (0)1932 865065
finnCap Ltd (nominated adviser & broker)          Geoff Nash / James Thompson	Tel: (0)207 220 0500

Notes for editors:

About Proteome Sciences plc (www.proteomics.com)

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.

Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.

The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPLLFERASIVIIE